QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “DNA and RNA Synthesizer- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global DNA and RNA Synthesizer market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for DNA and RNA Synthesizer was estimated to be worth US$ 303 million in 2025 and is projected to reach US$ 395 million, growing at a CAGR of 3.9% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5912631/dna-and-rna-synthesizer
DNA and RNA Synthesizer Product Introduction
A DNA and RNA synthesizer is an instrument used in laboratories to create synthetic DNA and RNA molecules. In simpler terms, it’s like a specialized printer that, instead of ink, uses nucleotides (the building blocks of DNA and RNA) to “print” desired genetic sequences.
According to the new market research report “Global DNA and RNA Synthesizer Market Report 2025-2031”, published by QYResearch, the global DNA and RNA Synthesizer market size is projected to reach USD 0.38 billion by 2031, at a CAGR of 3.9% during the forecast period.
Figure00001. Global DNA and RNA Synthesizer Market Size (US$ Million), 2025 VS 2031
Above data is based on report from QYResearch: Global DNA and RNA Synthesizer Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.
Figure00002. Global DNA and RNA Synthesizer Top 9 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)
Above data is based on report from QYResearch: Global DNA and RNA Synthesizer Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.
According to QYResearch Top Players Research Center, the global key manufacturers of DNA and RNA Synthesizer include Kilobaser, Polygen GmbH, Biolytic Lab Performance, K&A Labs GmbH, BIOSSET Ltd., CSBio, Cytiva, LGC Biosearch Technologies, Hunan Honya Biotech Co., Ltd. etc. DNA and RNA synthesizer manufacturing is concentrated in North America and Western Europe, with significant production and assembly growth in East Asia, because these regions have strong life-science instrument ecosystems, mature precision mechatronics, fluidics, and automation supply chains, deep biotech/pharma demand, rigorous quality and regulatory standards, and well-developed service/support networks that speed product commercialization and global scaling.
Table 1. DNA and RNA Synthesizer Industry Chain Analysis
| Item | Description | |
| Upstream | Raw Materials & Components | High-purity nucleotide precursors (DNA/RNA building blocks), coupling reagents (for oligonucleotide chain extension), microfluidic chips (for automated, high-throughput synthesis), precision fluidic pumps, optical detection modules (for real-time synthesis quality monitoring). |
| Technology & IP | Patented oligonucleotide synthesis chemistry (e.g., phosphoramidite method optimizations), microfluidic system design, and software algorithms for sequence-specific synthesis control. | |
| Midstream | Core DNA/RNA Synthesizer Manufacturing & Services | 1. Synthesizer Development & Production: Design and assembly of tiered systems (benchtop: small-batch, lab-scale; industrial: high-throughput, large-volume) with integrated automation (AI-driven sequence optimization, error correction).
2. Customization Services: Tailoring synthesizers for niche needs (long-read RNA/DNA synthesis, modified nucleotide integration for therapeutic applications) and high-throughput workflows (for CRO/bioprocessing clients). 3. Post-Sales Support: Maintenance, software updates (protocol expansion), and training for end-user lab teams. |
| Downstream | Academic Institution | - Applications: Basic life science research (gene cloning, CRISPR sgRNA synthesis), synthetic biology (gene circuit construction), genomics (NGS probe preparation), educational lab projects.
- Needs: Small-batch (10–1000nmol), diverse sequences, flexible modification options, user-friendly operation, cost-effectiveness. - Equipment Preference: Benchtop synthesizers or shared core facility high-throughput systems. |
| Pharmaceutical Company | - Applications: Nucleic acid drug R&D (mRNA vaccines, siRNA therapeutics), gene therapy (CRISPR vector synthesis), diagnostic assay production (qPCR primers).
- Needs: Large-scale (μmol–gram-level), GMP-compliant production, high purity (>99.5%), batch consistency, sequence traceability. - Equipment Preference: Industrial high-throughput synthesizers with integrated GMP data management systems. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 2. DNA and RNA Synthesizer Industry Policy Analysis
| Policy | Description | |
| 1 | US FDA “Guidance for Industry: CMC Information for Nucleic Acid-Based Gene Therapy Products (2024)” | Mandates that DNA/RNA synthesizers used in GMP production of nucleic acid APIs (e.g., mRNA, siRNA) must include validated process controls (batch tracking, error correction), integrated quality monitoring (real-time purity detection), and data integrity features (audit trails). This raises entry barriers for non-compliant equipment, pushing synthesizer manufacturers to develop GMP-specific models for pharmaceutical clients. |
| 2 | EU In Vitro Diagnostic Regulation (IVDR, 2022 Full Implementation) | Classifies synthesizers for diagnostic oligonucleotide production (e.g., NGS probes, qPCR primers) as “ancillary equipment” for IVDR-compliant products. It requires suppliers to provide equipment validation reports (performance, reliability) and sequence traceability documentation, expanding post-sales technical support demands for synthesizer manufacturers. |
| 3 | China NMPA “Guidelines for mRNA Vaccine Production Equipment Evaluation (2023)” | Specifies technical standards for synthesizers in mRNA vaccine production: high-throughput (≥100mg/batch mRNA), low nucleotide error rate (<0.1%), and compatibility with GMP data management systems. This favors domestic synthesizer firms (e.g., Huada Intelligence) with localized GMP-compliant models, while imported equipment faces stricter import validation. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 3. DNA and RNA Synthesizer Industry Development Trends
| Development Trends | Description | |
| 1 | Long-Sequence & High-Fidelity Enzyme-Based Synthesis Systems | Shift from traditional chemical (phosphoramidite) to enzyme-driven synthesis platforms, enabling longer DNA/RNA sequences (≥5kb for DNA, ≥1kb for RNA) with <0.05% error rates. For academic institutions: supports synthetic genome construction and complex gene circuit design. For pharmaceutical companies: enables large-scale, high-purity mRNA (vaccine) and long guide RNA (gene therapy) synthesis, cutting post-purification costs. |
| 2 | AI-Enhanced High-Throughput & Smart Error-Correction Workflows | Integrate machine learning (ML) into synthesizers to optimize sequence design (reduce secondary structure interference), automate 10,000+ sequence high-throughput library synthesis, and real-time error correction (via optical monitoring). Academic users accelerate synthetic biology library prep; pharmaceutical clients cut siRNA/ASO drug candidate screening timelines by 30–40%. |
| 3 | GMP-Compliant Integrated Industrial Synthesis Systems | Develop end-to-end industrial synthesizers (integrating synthesis, purification, and QC modules) with built-in GMP data management (audit trails, batch traceability). Tailored for pharmaceutical companies: supports gram-level nucleic acid API production (e.g., mRNA vaccines, gene therapy vectors) while meeting global regulatory standards, eliminating disjointed process bottlenecks. |
| 4 | Modular & Multi-Functional Benchtop Systems | Launch modular benchtop tools that switch between small-batch (10nmol) research synthesis, modified nucleotide integration (e.g., 2′-O-methyl RNA), and 96-well primer/probe production. Ideal for academic institutions (flexible, cost-effective for diverse projects) and small pharma R&D labs (adaptable tools for early-stage drug development). |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 4. DNA and RNA Synthesizer Industry Development Opportunities
| Development Opportunities | Description | |
| 1 | Academic-Focused Modular Synthesis Access Solutions | Launch cost-effective, modular benchtop synthesizer bundles (with detachable modification/long-sequence modules) paired with shared core facility licensing models. Target academic institutions: address budget constraints while enabling flexible access to complex capabilities (e.g., 2′-O-methyl RNA, 5kb DNA synthesis) for synthetic biology/genomics projects; include discounted training workshops for lab teams. |
| 2 | Pharma-Tailored GMP Long-Sequence Synthesis Co-Development | Partner with large pharmaceutical companies to co-engineer GMP-compliant enzyme-based synthesizers optimized for gram-level long-sequence mRNA/siRNA (≥1kb) production. Integrate in-line QC (real-time purity/error monitoring) and regulatory data management; lock in long-term supply contracts for commercial-scale nucleic acid API manufacturing (critical for next-gen vaccines/gene therapies). |
| 3 | AI-Optimized High-Throughput Library Synthesis Services for Biotech Startups | Offer on-demand, AI-driven oligonucleotide library synthesis services (using high-throughput synthesizers) for early-stage biotech startups. Provide custom library design (ML-optimized to reduce secondary structure), small-batch to mid-batch production, and basic QC – address startups’ need for cost-efficient, fast-turnaround libraries for drug target screening (without upfront equipment investment). |
| 4 | Regulatory-Validated Modified Nucleotide Synthesis Toolkits | Develop pre-validated synthesis toolkits (hardware modules + CMC documentation templates) for therapeutic-grade modified oligonucleotides (e.g., locked nucleic acids, phosphorothioates) used in ASO/siRNA drugs. Target pharmaceutical clients: reduce regulatory approval timelines by providing pre-qualified modification protocols, impurity profiles, and batch consistency data aligned with FDA/EMA guidelines. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 5. DNA and RNA Synthesizer Obstacles/Challenges to Industry Development
| Obstacles/Challenges | Description | |
| 1 | Technical Limitations in Long-Sequence & High-Fidelity Synthesis | Despite enzyme-based advances, scaling long DNA/RNA (≥5kb) synthesis with <0.05% error rates remains technically challenging; integrating modified nucleotides (critical for therapeutic oligonucleotides) often yields low purity/inconsistent batches. This limits pharmaceutical clients’ ability to develop complex nucleic acid drugs (e.g., long-acting mRNA vaccines) and academic researchers’ progress in synthetic genome projects. |
| 2 | Cost Accessibility Gaps for Diverse Downstream Users | Academic institutions face prohibitive costs for advanced synthesizers (long-sequence/modified nucleotide capabilities), restricting access to cutting-edge synthetic biology/genomics research; small-to-mid biotech/pharma firms cannot afford GMP-compliant industrial systems (upfront costs >$1M), blocking their entry into nucleic acid drug development. |
| 3 | Regulatory Compliance Burdens for GMP-Targeted Equipment | Midstream manufacturers must meet strict global regulatory standards (FDA/EMA/NMPA) for pharma-focused synthesizers (e.g., mandatory audit trails, batch traceability, process validation). This requires massive investments in R&D, documentation, and specialized post-sales support—resources smaller manufacturers lack, widening the market gap between large (global) and small (regional) players. |
| 4 | Upstream Supply Chain Vulnerabilities | The industry relies on a concentrated base of suppliers for high-purity nucleotides, specialized microfluidic chips, and precision fluidic components. Supply disruptions (e.g., post-pandemic raw material shortages, export restrictions) delay midstream synthesizer production; this increases lead times for downstream users (academic labs waiting for benchtop tools, pharma firms needing GMP systems for clinical trials). |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The DNA and RNA Synthesizer market is segmented as below:
By Company
Kilobaser
Polygen GmbH
Biolytic Lab Performance
K&A Labs GmbH
BIOSSET Ltd.
CSBio
Cytiva
LGC Biosearch Technologies
Hunan Honya Biotech Co., Ltd.
Segment by Type
Laboratory Grade
Industrial Grade
Large-scale Synthesis Grade
Segment by Application
Academic Institution
Pharmaceutical Company
Others
Each chapter of the report provides detailed information for readers to further understand the DNA and RNA Synthesizer market:
Chapter 1: Introduces the report scope of the DNA and RNA Synthesizer report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of DNA and RNA Synthesizer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various DNA and RNA Synthesizer market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of DNA and RNA Synthesizer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of DNA and RNA Synthesizer in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth DNA and RNA Synthesizer competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides DNA and RNA Synthesizer comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides DNA and RNA Synthesizer market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global DNA and RNA Synthesizer Market Research Report 2026
Global DNA and RNA Synthesizers Market Research Report 2026
DNA and RNA Synthesizers- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Global Automated DNA and RNA Synthesizer Market Research Report 2026
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
